BioMed Central is pleased to announce the publication of Sydney Brenners autobiography

Today one of the worlds most famous living biologists, Sydney Brenner, publishes his scientific autobiography with BioMed Central (www.biomedcentral.com).

A giant of modern biology, Sydney has contributed enormously to the fields of molecular and developmental biology over the past 50 years. Famously, he identified and named 'messenger RNA', which is crucial for converting the genetic code of DNA into proteins. Later, shifting direction in his research, he pioneered the use of the nematode worm Caenorhabditis elegans as a model organism for developmental biology - an animal that is now the focus of work for over 1000 researchers across the globe.

My Life in Science, as the autobiography is called, offers a unique window into the world of scientific discovery. Sydney vividly takes us through intense discussions with other, world-renowned scientists, the frustration of disappointing experiments and the intense build-up to that 'Eureka!' moment. We follow him from his modest beginnings, living in his fathers shoe shop in South Africa, to the heights as director of the MRC Laboratory of Molecular Biology in Cambridge, England and beyond.

This entertaining account captures the essence of a renowned scientist and captivating raconteur who has achieved something of a cult status within the biomedical community. His sharp wit and withering humour on the subject of the researchers lot appeared for many years in the columns of the journal Current Biology. Now, finally, we have a chance to hear his own story, in his own words.


Contact: Gordon Fletcher
BioMed Central

Page: 1

Related biology news :

1. BioMed Central to consult funders and librarians over Open Access payment model
2. LA BioMed Medical/Research Briefs, July/August 2004
3. BioMed Central explodes Open Access myths
4. The Scientist and BioMed Central come together to publish high-impact magazine
5. BioMed Central to deposit e-journals with the British Library
6. BioMed Central to consider charging authors for paper submissions
7. Get Research on the move with BioMed Central
8. BioMed Central to launch at microbiology meeting
9. BioMed Central to free scientists and clinical researchers from copyright restrictions
10. USAID, Conservation International & Starbucks launch Conservation Coffee Alliance in Central America
11. Sediments in many Central Valley streams contain toxic levels of pyrethroid pesticides

Post Your Comments:

(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 8.8% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology:
Cached News: